TY - JOUR
T1 - Transition of care of patients with eosinophilic gastrointestinal diseases
T2 - Challenges and opportunities
AU - Hiremath, Girish
AU - Chapa-Rodriguez, Adrian
AU - Katzka, David A.
AU - Spergel, Jonathan M.
AU - Gold, Benjamin
AU - Bredenoord, Albert J.
AU - Dellon, Evan S.
AU - Huang, Jeannie
AU - Gupta, Sandeep K.
N1 - Funding Information: G.H.: No potential conflicts for this project. Full disclosures as follows: Consultant: Sanofi Genzyme, Regenron, Allakos, Shire/Takeda. A. C-R.: No potential conflicts for this project. D.K.: Received consulting fees from Adare, Phathom, Takeda and Celgene. J.M.S.: Received research funding from NIH, FARE, Regeneron, Sanofi, Novartis and consulting fees from Regeneron, Sanofi, Takeda, and Novartis. B.G.: Received consulting and/or speaking fees from Johnson&Johnson, Diasorin Molecular, Nestle Nutrition, Nutricia North America, Mead Johnson Nutrition, Evolve Biosystems, Inc., and Ironwood Pharmaceuticals. A.B.: Received research funding from Nutricia, Norgine, Thelial, SST and Bayer and received speaker and/or consulting fees from Laborie, Arena, EsoCap, Medtronic, Dr. Falk Pharma, Calypso Biotech, Alimentiv, Sanofi, Reckett Benkiser, Regeneron and AstraZeneca E.S.D.: No potential conflicts for this project. Full disclosures as follows: Research funding: Adare/Ellodi, Allakos, AstraZeneca, GSK, Meritage, Miraca, Nutricia, Celgene/Receptos/BMS, Regeneron, Shire/Takeda; Consultant: Abbott, Adare/ Ellodi, Aimmune, Allakos, Amgen, Arena, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/BMS, Celldex, Eli Lilly, EsoCap, GSK, Gossamer Bio, Landos, Morphic, Parexel/Calyx, Regeneron, Robarts/Alimentiv, Salix, Sanofi, Shire/Takeda; Educational grant: Allakos, Banner, Holoclara. J.H.: Received research funding from Gilead, Janssen, and Abbvie. S.K.G.: Consultant Adare, Allakos, Celgene, Gossamer Bio, QOL, UpToDate, Medscape, Viaskin. Research support from Shire and NIH U54 grant to CEGIR. Publisher Copyright: © 2022-IOS Press. All rights reserved.
PY - 2022
Y1 - 2022
N2 - Eosinophilic gastrointestinal disorders (EGID) are a group of allergen-mediated conditions which are characterized by eosinophilic inflammation affecting one or more parts of the gastrointestinal tract. A disproportionately higher number of EGID patients are diagnosed in the pediatric age group. Given the chronic course of EGIDs and lack of curative therapies at this time, majority of the pediatric EGID patients may require continued care well into their adulthood. However, to date, scant data are available regarding the health care transition (HCT), the transition of care (TC), and the effectiveness of transfer of care EGID patients from pediatric-oriented to adult-oriented providers. Herein, we review the lessons learnt from transfer of care of children with other chronic gastrointestinal and allergic conditions, analyze the current knowledge, potential barriers, the role of various stakeholders in successful transfer of care of EGID patients, propose a conceptual framework for HCT and TC of EGID patients, and identify outcome measures to ensure the quality of progression of care.
AB - Eosinophilic gastrointestinal disorders (EGID) are a group of allergen-mediated conditions which are characterized by eosinophilic inflammation affecting one or more parts of the gastrointestinal tract. A disproportionately higher number of EGID patients are diagnosed in the pediatric age group. Given the chronic course of EGIDs and lack of curative therapies at this time, majority of the pediatric EGID patients may require continued care well into their adulthood. However, to date, scant data are available regarding the health care transition (HCT), the transition of care (TC), and the effectiveness of transfer of care EGID patients from pediatric-oriented to adult-oriented providers. Herein, we review the lessons learnt from transfer of care of children with other chronic gastrointestinal and allergic conditions, analyze the current knowledge, potential barriers, the role of various stakeholders in successful transfer of care of EGID patients, propose a conceptual framework for HCT and TC of EGID patients, and identify outcome measures to ensure the quality of progression of care.
KW - Eosinophilic gastrointestinal diseases
KW - eosinophilic esophagitis
KW - health care transition
KW - transfer of care
KW - transition of care
UR - http://www.scopus.com/inward/record.url?scp=85128826528&partnerID=8YFLogxK
U2 - https://doi.org/10.3233/TRD-220054
DO - https://doi.org/10.3233/TRD-220054
M3 - Article
SN - 2214-6490
VL - 6
SP - 13
EP - 23
JO - Translational Science of Rare Diseases
JF - Translational Science of Rare Diseases
IS - 1-2
ER -